Compare ADMA Biologics Inc (ADMA) vs NetEase Inc (NTES) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs NetEase Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while NetEase Inc trades at $133.01 (market cap $83.83B). The key difference: NetEase Inc is far larger — about 39.4× ADMA Biologics Inc's market cap, and NetEase Inc pays a 2.31% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NTES | |
|---|---|---|
Market Cap | $2.13B | $83.83B |
Sector | Health | Media |
52-Week High | $20.38 | $159.34 |
52-Week Low | $7.60 | $109.26 |
Enterprise Value | $2.20B | $60.31B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
NetEase (NTES) trades at $130.82, up 2.81% today, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings that beat estimates, with revenue growth to $112.63B in 2025 and a net income margin of 29.84%. Recent news highlights international expansion and a $0.72 dividend payment scheduled for June 2026.
The stock presents a compelling value with a P/E of 16.83 and robust profitability metrics. Analyst consensus is strongly bullish with 82% buy ratings and a 34.7% upside potential. Key risks include reliance on the Chinese market and competitive pressures in gaming. Cash flow trends show volatility, but the balance sheet remains strong with $137.58B in cash.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
